Online inquiry

IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7552MR)

This product GTTS-WQ7552MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GPC3 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164617.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2719
UniProt ID P51654
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7552MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12948MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ4118MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ2469MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ15278MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ15289MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ10245MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ11213MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ12777MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW